 NEWTON, Mass., Aug. 10, 2021 GLOBE NEWSWIRE -- Allena Pharmaceuticals, Inc. NASDAQ: ALNA Allena or the Company, a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate progress. 